Type2 diabetes
Conditions
Interventions
beta-cryptoxanthin containing beverages
placebo
Sponsors
Brain/Liver Interface Medicine Research Center, Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.HbA1C<8.0% within 8 weeks before the start of test 2.treated with diet and exercise or oral hypoglycemic agents for 12 weeks or longer 3.Outpatient 4. That drinking fruit juice of 16 weeks or more are possible
Exclusion criteria
Exclusion criteria: 1.hypersensitivity to components of the juice 2.history of type 1 diabetes or glucose intolerance and gestational diabetes 3.history of ketoacidosis 4.history of hypoglycemia severe symptoms associated with loss of consciousness or coma 5.poorly controlled diabetes 6. poorly controlled hypertension, systolic blood pressure >160 mmHg, or diastolic blood pressure >100 7.patients with grade 3 or more of the Ministry of Health, Labour and Welfare drug side effects classification serious complication 8.pregnancy or breast feeding 9.inability to participate in the study as assessed by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of insulin resistance(HOMA-IR)and insulin secretion(HOMA-beta) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Changes in the physical findings(Body weight/waist circumference/Blood pressure/ Heart rate/The body composition by impedance method) 2. change of glycemic state(FPG, HbA1C) 3.Change og liver function (AST ALT GTP) 4.Change ofLipid metabolism(TC, HDL-C, TG, sdLDL) 5.Safety and adverse events 6.Change of Renal function (eGFR) 7.Change of oxidative stress marker (U-8OHDG) 8.Changes in blood cytokine (Adiponectin) 9. Dietary intake-ratio | — |
Countries
Japan
Contacts
Public ContactTsuguhito Ota
Kanazawa University Hospital Department of Medicine
Outcome results
None listed